(Q37738571)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

Clinical implications of c-Kit mutations in acute myelogenous leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Daniel Steinbach

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Selim Corbacioglu

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

Current hematologic malignancy reports

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

77-82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11899-009-0011-8

1 February 2020

exact match

0 references

cites work

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11899-009-0011-8

Rapamycins: mechanism of action and cellular resistance

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11899-009-0011-8

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11899-009-0011-8

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

21 January 2018

1 reference

12 December 2020

Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin

1 reference

12 December 2020

In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia.

1 reference

12 December 2020

Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable

1 reference

12 December 2020

Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases

1 reference

12 December 2020

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

1 reference

12 December 2020

Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell

1 reference

12 December 2020

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

1 reference

12 December 2020

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

1 reference

12 December 2020

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

1 reference

12 December 2020

ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?

1 reference

12 December 2020

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

1 reference

12 December 2020

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways

1 reference

12 December 2020

Genetics of myeloid leukemias

1 reference

12 December 2020

KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group

1 reference

12 December 2020

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

12 December 2020

Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia

1 reference

12 December 2020

Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML.

1 reference

12 December 2020

c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia

1 reference

12 December 2020

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

1 reference

12 December 2020

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

1 reference

12 December 2020

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

12 December 2020

Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia.

1 reference

12 December 2020

C-kit mutations in core binding factor leukemias

1 reference

12 December 2020

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

1 reference

12 December 2020

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

1 reference

12 December 2020

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia

1 reference

12 December 2020

Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571).

1 reference

12 December 2020

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

12 December 2020

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

1 reference

12 December 2020

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

1 reference

12 December 2020

TOR signaling in growth and metabolism

1 reference

12 December 2020

Defining the role of mTOR in cancer

1 reference

12 December 2020

Cancer-susceptibility genes. Gatekeepers and caretakers

1 reference

12 December 2020

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

1 reference

12 December 2020

Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia

1 reference

12 December 2020

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia

1 reference

12 December 2020

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

1 reference

12 December 2020

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

1 reference

12 December 2020

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

1 reference

12 December 2020

Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration

1 reference

12 December 2020

Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model

1 reference

12 December 2020

Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells

1 reference

12 December 2020

Initial testing of dasatinib by the pediatric preclinical testing program

1 reference

12 December 2020

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas

1 reference

12 December 2020

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

1 reference

12 December 2020

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

12 December 2020

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

12 December 2020

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

1 reference

12 December 2020

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia

1 reference

12 December 2020

10.1007/S11899-009-0011-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425418%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference